VenterD.J., TuziN.I., KumarS.: Overespression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet1987; 2: 69–72.
2.
BiancoA.R., De LaurentisM., CarlomagnoC.: 20 years update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Proc Am Soc Clin Onc1998, 17: 97a.
3.
GustersonB.A., GelberR.D., GoldhirschK.N.: Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol.1992; 10: 1049–1056.
4.
ThorA.D., BerryD.A., BudmanD.R.: erbB-2, p53 and efficacy of adjuvant therapy in lymphnode positive breast cancer. J. Natl. Cancer Inst.1998; 90: 13346–13360.
5.
SeidmanA.D., BaselgaJ., YaoT.Y.: HER-2 /neu overexpression and clinical taxane sensitivity. A multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol1996; 15: 104a.
6.
SlamonD., Leyland-JonesB., SharkS.: Addition of Herceptin to first line chemotherapy for HER-2 overex-pressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin One1998; 17: 377.
7.
SlamonD., Leyland-JonesB., ShakeS.: Addition of Herceptin to first line chemotherapy for HER2 overex-pressing metastatic breast cancer markedly increase anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol1998; 17: 98a (a377).
8.
SlamonD.J., ClarkG.M., WongS.G.: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science1987; 235: 177–182.
9.
NortonL., SlamonD., Leyland-JonesB.: Overall survival advantage to simultaneous chemotherapy plus the humanizad anti-HER” monoclonal antibody Herceptin in HER″-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol1999, 18: a483.
10.
VogelC., CobleighD., TripathyL.: First line single agent trastuzumab therapy for women with HER-2 ove-rexpressing metastatic breast cancer. Proc Am Clin Oncol2000; 19: 275a.
11.
MassR.D., SandersC., CharleneK., JonsonL.: The concordance between the clinical trials assai (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol2000, 19: A291.
12.
FuchsI., LandtS., BuehlerH.: HER-2 expression in the myocardium as a cause for the cardiotoxicity of trastuzumab?Proc Am Clin Oncol2000, 19: 393a.
13.
Leyland-JonesB., ArnoldA., GelmonK.: A pharmacokinetic study of trastuzumab administred with pacli-taxel iv every 3 weeks. Eur J Cancer2000, 36(5): a176.
14.
BlumJ.L., JonesS.E., BuzardA.U.: Multicentre phase I study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol1999; 17(2): 485–493.
15.
O'ReillyS.M., MoiseyenkoV., TalbotD.C.: A randomized phase II study of Xeloda (capecitabine) vs pacli-taxel in breast cancer patients failing previous anthracy-cline therapy. Proc Am Soc Clin Oncol1998, 17: a627.
16.
O'ShaughnessyJ., MoiseyenkoV., BellD.: A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in woman aged >55 years. Proc Am Soc Clin Oncol1998; 17: 103a.
17.
VenturiniM., Del MastroL., MerlanoM.: Dose finding study of capecitabine in combination with doce-taxel and epirubicin in prior untreated advanced breast cancer patients. Proc Am Soc Clin Oncol2000; 19: 419a.
18.
NoleF., CataniaC., MandaleM.: Phase I study of vi-norelbine and capecitabine in advanced breast cancer. Proc Am Soc Clin Oncol2000, 19: 428a.
